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Abstract
Jervell-Lange Nielsen syndrome (JLNS) with autosomal recessive inheritance is a
congenital cardiovascular disorder characterized by prolongation of QT interval on
the ECG and deafness. We have performed molecular investigation by haplotype
analysis and DNA Sanger sequencing in 2 unrelated Iranian families with a history
of syncope. Mutational screening of KCNQ1 gene revealed the novel homozygous
frameshift mutation c.733-734delGG (p.G245Rfs*39) in 2 obviously unrelated cases
of JLNS which is probably a founder mutation in Iran. The novel mutation detected
in this study is the first time reported among Iranian population and will be benefi-
cial in the tribe and region-specific cascade screening of LQTS in Iran.
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1 | INTRODUCTION
The congenital long-QT syndrome (LQTS), a prolongation of the QT
interval at electrocardiogram (ECG), is a severe cardiac arrhythmia.1
Inherited LQTS have been characterized in 2 forms: autosomal-domi-
nant Romano-Ward syndrome (RWS) and Jervell-Lange Nielsen syn-
drome (JLNS). Romano-Ward syndrome (MIM# 192500) is the most
common form of inherited LQTS, with an estimated incidence of
1:5000-1:10 000 live births. JLNS (MIM# 220400) is less prevalent
(1:50.000). In these patients, LQTS is associated with congenital
sensorineural deafness, and the pattern of inheritance is autosomal
recessive.2
In 1993, Schwartz et al3 developed the diagnostic criteria for
clinical diagnosis of LQTS that is essential to identify asymptomatic
carriers. LQTS is characterized by some features including extended
QT interval and T-wave alteration in ECG, syncope, ventricular
tachycardia (VT), torsade de points (TdP) and an increased risk
of sudden death due to TdP or VT.4 So far, a panel of sixteen
candidate genes has been known that heterozygous mutations in
them cause Romano-Ward syndrome and mainly 2 genes that
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homozygous or compound heterozygous mutations in them are
responsible for Jervell and Lange-Nielsen syndrome.5,6 Mutations
that lead to defects in cardiac rapidly (IKr) and slowly (IKs) activating
delayed rectifier potassium channels and sodium channel (INa) can
cause Romano-Ward syndrome while Jervell and Lange-Nielsen
syndrome solely is caused by defects in IKs that is crucial electrical
part of cardiac action potential as well as indispensable for myocar-
dial repolarization.7,8
The most commonly mutated gene among causative genes for
LQTS is KCNQ1.9-11 It encodes the subunit of the slow delayed rec-
tifier potassium channel. KCNQ1 has 6 transmembrane segments,
and combination of normal and mutant subunits results in the
incomplete formation of the channel and consequently loss of chan-
nel function.7
Based on clinical and molecular findings and exact diagnosis,
treatment of JLNS will be managed. In this study, we managed to
discover a homozygous frameshift deletion in KCNQ1 gene in 2 Ira-
nian JLNS patients for the first time.
2 | MATERIALS
2.1 | Patients
Two unrelated LQTS patients were referred to the emergency unit
at the Rajaei Cardiovascular Medical and Research Center, Tehran,
Iran, for further clinical evaluations:
2.1.1 | Patient 1
The first proband was a 5-year-old boy who was referred to our
center due to syncope. The medical history showed recurrent brady-
cardia during the fetal period, syncope, and cochlear implantation at
4 for management of sensory-neural hearing loss. There was no fam-
ily history of syncope, faint or sudden death in 5 generations. In the
paraclinical studies, the level of electrolytes and hormone analysis
was in normal range. Resting 12-lead electrocardiogram (ECG) dis-
played a manifestly prolonged QTc interval of more than 600 ms
(corrected by Bazett’s formula) and T-wave alternant (Figure 1A).
Also, a structurally normal heart was detected by echocardiography
report. The ECG of his asymptomatic parents showed a totally nor-
mal electrocardiogram. Propranolol with the dose of 3 mg/kg/d,
divided 3 times a day, was started for the patient. An endocardial
single-chamber implantable cardioverter defibrillator (ICD) was
implanted to prevent any life-threatening events.
2.1.2 | Patient 2
The proband was a 3-year girl with recurrent syncopes and congeni-
tal neurosensory deafness. She had a QTc interval of 540-560 ms
(corrected by Bazett’s formula) and T-wave alternant on V1-V4 (Fig-
ure 1B). She had a history of fainting, while she was in the bath and
during exercise. Her first syncope episode had occurred at
19 months of age. Physical and neurological examinations were
normal except for hearing impairment, and she did not have an elec-
trolyte imbalance. At 15 months of age, she received a cochlear
implant. Echocardiography showed a structurally normal heart.
2 mg/kg/d beta-blocker treatment (maximum dose of tolerate by
this patient) was started divided 3 times per day. Her parents were
asymptomatic, and their QTc intervals were in normal range. There
were no other siblings, and members of the extended family were
not available for study.
3 | GENETIC STUDY
After obtaining written informed consent, blood samples of the
patients and other family members were collected and genomic
DNA was extracted by salting-out method.12 At first, for haplotype
analysis, linked short tandem repeat (STR) markers surrounding the
KCNQ1 gene were used. All STRs were selected among tetra-nucleo-
tide repeat markers and were unique. Marker D11SI was an intra-
genic marker, while the other markers were selected by a maximum
physical distance of less than 1.4 Mb at the upstream (D11SU0.6) or
downstream (D11SD13.6, D11SD8.3) of the gene. Detecting the size
of the repeats was performed by ABI 3130XL Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). Then, primer pairs for all
coding exons and exon-intron boundaries and untranslated regions
of KCNQ1 [NM_000218] gene were designed by primer 3 Online
and gene runner software. All of the KCNQ1 gene exons were ampli-
fied by PCR, and the amplicons were directly sequenced by Sanger
sequencing chain termination method on ABI 3130XL Genetic Ana-
lyzer by Kawsar Biotech Co. (KBC, Tehran, Iran).13 The results of
Sanger sequencing were analyzed and compared against the RefSeq
genomic accession numbers (NG_008935.1), and mutation database
(http://www.genomed.org/lovd2/home.php) was used for evaluating
the variants.
4 | RESULTS
Haplotype analysis by 6 linked STR markers surrounding the KCNQ1
gene showed the disease in the family is linked to the KCNQ1 gene.
Sanger sequencing of the 2 probands showed a novel homozygous
mutation, c.733-734delGG (p.G245Rfs*39), in exon 5 of KCNQ1
gene (ClinVar accession number: SCV000584046). The 2-bp deletion
results in a frameshift deletion (G245Rfs*39) in the cytoplasmic loop
(C loop) between the transmembrane region (S4-S5 C loop) of
KvLQT1 (KCNQ1 protein) (Figure 2). This mutation introduces 38
novel amino acids after codon 244 (glycine 245 as the first affected
amino acid has altered into Arginine) and premature stop codon at
283 that resulted in a truncated protein. This mutation was also
found in heterozygous form in the parents of 2 probands
(Figure 3C).
Short tandem repeat markers help us demonstrating the same
frameshift KCNQ1 mutation in 2 obviously unrelated families derives
from a unique origin (founder mutation) (Figure 3).
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5 | DISCUSSION
Long-QT syndrome includes a variety of diseases caused by mutations
in cardiac ion channels. Among the genes encoding ion channels of
the heart, homozygous or compound heterozygous mutations in
KCNQ1 and KCNE1 genes are responsible for the recessive type of
LQTS known as JLNS. These 2 genes encode subunits responsible for
a voltage-gated potassium channel formation, as the potassium cur-
rent is the fundamental part of the cardiac repolarization and normal
function of inner ear cells. In addition, it has an essential role to speed
up the activating potassium current (IKs).14,15 Mutations in either the
KCNQ1 or KCNE1 genes affect potassium transport in the inner ear
and cardiac muscle, causing deafness and an irregular heart rhythm.16
So far, 21 different homozygous or compound heterozygous
mutations in KCNQ1 gene and 3 homozygous or compound
heterozygous mutations in KCNE1 gene in JLNS patients have been
characterized according to the Human Genome Database (HGMD),
http://www.hgmd.cf.ac.uk/ac/index.php).17
In this study, we have identified a homozygous frameshift muta-
tion in exon 5 (c.733-734delGG) of the KCNQ1 gene in 2 noncon-
sanguineous families with JLNS among an Iranian cohort of LQTS
patients. The mutation has not been reported previously in HGMD
and 1000 genomes databases. This mutation occurs in the cytoplas-
mic loop(C loop) between the transmembrane regions (S4-S5 C loop)
of KCNQ1. As C loops are critical in modifying the function of volt-
age-gated potassium channels, changing the C loop residues by
mutations in this area of KCNQ1 gene, effects on the voltage depen-
dence of channel activation, leads to increased risk for lethal cardiac
events.18 Although functional assays of mutation were not con-
ducted in these patients, however frameshift mutations, with an esti-
mated predicted value (EPV) of 99%, were expected to have a
pathogenic effect.19
Electrophysiological study revealed that mutations in the S4-S5
linker, W248R, and E261K, changed the voltage dependence of
KCNQ1 channels and caused deactivation of KCNQ1.20 It has been
reported that missense mutations in the S4-S5 linker, V254M, led to
F IGURE 1 ECG of the patients. A, The 12-lead electrocardiogram of the patient A at 5 years of age demonstrating prolonged QTc interval
(QTc>600 ms, heart rate: 62 beats/min) and T-wave alternancy. B, The 12-lead electrocardiogram of the patient B at 3 years of age
demonstrating prolonged QTc interval; QTc>520 ms, heart rate: 72 beats/min (with a paper speed of 25 mm/s and 10 mm/mV at 20 Hz)
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loss of function; however, mutant subunits along with the wild-type
KCNQ1 expedited the ratio of channel activation.21Therefore, as
Sanguinetti et al22 described, such as KCNH2, missense mutations in
the S4-S5 linker of KCNQ1 can either slack or expedite channel acti-
vation.20 Moreover, other functional assay demonstrated that muta-
tions in C loops of KCNQ1 gene, in the absence23 and presence of
wild-type subunits, significantly impressed adrenergic channel regula-
tion.24 As JLNS patients tend to have mutations that cause frame-
shifts25 and/or protein truncation26 and it was suggested that
truncating mutations result in loss of function,27 in this report, sup-
port for this concept is provided. In both families, a frameshift muta-
tion is present, with the truncating mutation leading to QT
prolongation in affected individuals. In 2006, one report presented
the guidelines that suggested an experimental b-blockers therapy in
all LQTS patients,28 meanwhile another study proved the effect of
beta-blockers on affected individuals who have mutations in the C
loops collated with mutations in another location that can decline
the risk of lethal cardiac incidents.24 According to previous studies,6
patients with JLNS carrying KCNQ1 mutations are at particularly high
risk, and therefore, special aids, including beta-blocker therapy, may
be supposed necessary because of the high recurrence rate of fatal
arrhythmia. Both of our cases were treated with propranolol or in
one instance ICD. During 1 year using propranolol therapy follow-up
of these patients, any cardiac events were recorded. Unfortunately,
although Left cardiac sympathetic denervation (LCSD) helps to
reduce life-treating events in such cases, but we did not do it nowa-
days in our centers.
G245Rfs*39 mutation in LQTS patients has not been previously
reported and appears to be a novel mutation. This mutation deletes
2 nucleotide GG between nucleotide position 733 and 734, resulted
in a premature stop codon at position 283 that lead to the produc-
tion of a truncated protein containing a total of 282 amino acids
which its size is less than half of normal protein. Parents of 2
patients are heterozygous for the mutation (Figure 2C). They are
asymptomatic, and ECG from the parents showed QTcs within nor-
mal limits. The 2 patients analyzed in this report are not resource-
fully linked, haplotype analysis by linked STR markers surrounding
the KCNQ1 gene, demonstrating that the source of the mutation in
both patients is the same. In addition, according to the previous
statement,29 in such a huge endogamous community in which con-
sanguineous marriages are common, we would expect the same
mutation in 2 apparently unrelated families originate from a unique
source and could be a founder mutation. Both of families are from
the southwestern of Iran (Khuzestan Province).
In summary, in the current study for the first time, we have iden-
tified a novel homozygous frameshift mutation in the KCNQ1 gene
in 2 Iranian patients with JLNS which expected to cause consequen-
tial structural changes in the encoded potassium channel subunit,
and regards to ACMG, this finding is likely to severely diminish or
abolish channel function. Based on the results of our study and pre-
vious studies, it is imperative to perform proper genetic analysis to
confirm the diagnosis in order to select the optimal method for clini-
cal care of the patient.
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